© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 1, 69-73,
January 5, 2000
© 2000 Oxford University Press
BRIEF COMMUNICATION |
Biochemopreventive Therapy for Patients With Premalignant Lesions of the Head and Neck and p53 Gene Expression
Affiliations of authors: D. M. Shin, L. Mao, V. M. Papadimitrakopoulou, J. S. Lee, W. K. Hong (Department of Thoracic/Head and Neck Medical Oncology), G. Clayman, A. Gillenwater, J. Myers (Department of Head and Neck Surgery), A. El-Naggar, H. J. C. Shin (Department of Pathology), J. J. Lee (Department of Biostatistics), S. M. Lippman (Department of Clinical Cancer Prevention), W. N. Hittelman (Department of Clinical Investigation). The University of Texas M. D. Anderson Cancer Center, Houston.
Correspondence to: Dong M. Shin, M.D., Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Box 80, 1515 Holcombe Blvd., Houston, TX 77030.
Oral premalignant lesions are a useful model for developing
chemoprevention trials involving lesions throughout the upper
aerodigestive tract (1). These lesions most often develop in
association with exposure to carcinogens, such as tobacco and alcohol,
and frequently precede the development of invasive carcinoma
(2,3). Although early oral premalignant lesions (hyperplasia
and mild dysplasia) are particularly responsive to single-agent
retinoid therapy (4-8), advanced oral premalignant lesions
(i.e., moderate to severe dysplasia) are known to be resistant to
single-agent retinoid therapy (9,10). Since the combination of
retinoids and interferons (IFNs) has been shown to have an enhancing
effect on the induction of cell differentiation and on the suppression
of cell proliferation as seen in preclinical (10-14) and
clinical (15-17) studies, we designed a biochemoprevention
study for testing a combination of
NOTES
REFERENCES
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. S. Shumway, L. A. Kresty, P. E. Larsen, J. C. Zwick, B. Lu, H. W. Fields, R. J. Mumper, G. D. Stoner, and S. R. Mallery Effects of a Topically Applied Bioadhesive Berry Gel on Loss of Heterozygosity Indices in Premalignant Oral Lesions Clin. Cancer Res., April 15, 2008; 14(8): 2421 - 2430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C Maley Open questions in oesophageal adenocarcinogenesis Gut, July 1, 2007; 56(7): 897 - 898. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Rhee, F. R. Khuri, and D. M. Shin Advances in Chemoprevention of Head and Neck Cancer Oncologist, June 1, 2004; 9(3): 302 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Tsao, E. S. Kim, and W. K. Hong Chemoprevention of Cancer CA Cancer J Clin, May 1, 2004; 54(3): 150 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Manor, E. N. Shmidt, A. Budhu, A. Flesken-Nikitin, M. Zgola, R. Page, A. Yu. Nikitin, and N. Noy Mammary Carcinoma Suppression by Cellular Retinoic Acid Binding Protein-II Cancer Res., August 1, 2003; 63(15): 4426 - 4433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Izzo, V. A. Papadimitrakopoulou, D. D. Liu, P. L. C. den Hollander, I. M. Babenko, J. Keck, A. K. El-Naggar, D. M. Shin, J. J. Lee, W. K. Hong, et al. Cyclin D1 Genotype, Response to Biochemoprevention, and Progression Rate to Upper Aerodigestive Tract Cancer J Natl Cancer Inst, February 5, 2003; 95(3): 198 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Spinella, J. S. Kerley, K. A. White, and J. C. Curtin Retinoid Target Gene Activation during Induced Tumor Cell Differentiation: Human Embryonal Carcinoma as a Model J. Nutr., January 1, 2003; 133(1): 273S - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Papadimitrakopoulou, D. D. Liu, L. Mao, D. M. Shin, A. El-Naggar, H. Ibarguen, J. J. Lee, W. K. Hong, and W. N. Hittelman Biologic Correlates of a Biochemoprevention Trial in Advanced Upper Aerodigestive Tract Premalignant Lesions Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1605 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman and W. Ki Hong Cancer Prevention by Delay : Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002. Clin. Cancer Res., February 1, 2002; 8(2): 305 - 313. [Full Text] [PDF]
|
|
|
|
|
|
J. G. Einspahr, M. A. Nelson, K. Saboda, J. Warneke, G. T. Bowden, and D. S. Alberts Modulation of Biologic Endpoints by Topical Difluoromethylornithine (DFMO), in Subjects at High-Risk for Nonmelanoma Skin Cancer Clin. Cancer Res., January 1, 2002; 8(1): 149 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Shin, F. R. Khuri, B. Murphy, A. S. Garden, G. Clayman, M. Francisco, D. Liu, B. S. Glisson, L. Ginsberg, V. Papadimitrakopoulou, et al. Combined Interferon-Alfa, 13-cis-Retinoic Acid, and Alpha-Tocopherol in Locally Advanced Head and Neck Squamous Cell Carcinoma: Novel Bioadjuvant Phase II Trial J. Clin. Oncol., June 15, 2001; 19(12): 3010 - 3017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Shin, N. Charuruks, S. M. Lippman, J. J. Lee, J. Y. Ro, W. K. Hong, and W. N. Hittelman p53 Protein Accumulation and Genomic Instability in Head and Neck Multistep Tumorigenesis Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 603 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Hong, M. R. Spitz, and S. M. Lippman Cancer Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets J. Clin. Oncol., November 1, 2000; 18(90001): 9s - 18. [Full Text] [PDF]
|
|